Stock Watch: Class Of 2016 FDA Approvals Seller Beware: Ignore Your Market At Your Peril 08 Jun 2021 • By Andy Smith Revenues are still elusive for a surprising number of the novel drugs approved by the FDA five years ago. Emergent safety issues and confirmatory clinical trial failures were less common than lack of competitiveness as the main reason for revenue weakness. ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS
Andy Smith
As seen in:
Fandom,
British Journal of Sports Medicine,
ZDNet,
Citeline,
Scrip,
Providence Business News,
WV Living
H/C analyst after Principal in pricing & market access, H/C fund manager, Scrip columnist & pharma. The other half of the smithandsheridan.eu podcast
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Andy
Contact Andy, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack